| __timestamp | Agios Pharmaceuticals, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 675200000 |
| Thursday, January 1, 2015 | 35992000 | 771800000 |
| Friday, January 1, 2016 | 50714000 | 1205500000 |
| Sunday, January 1, 2017 | 71124000 | 1146500000 |
| Monday, January 1, 2018 | 114145000 | 1125800000 |
| Tuesday, January 1, 2019 | 132034000 | 1166100000 |
| Wednesday, January 1, 2020 | 149070000 | 1175500000 |
| Friday, January 1, 2021 | 121445000 | 1111400000 |
| Saturday, January 1, 2022 | 121673000 | 1210100000 |
| Sunday, January 1, 2023 | 119903000 | 1274600000 |
| Monday, January 1, 2024 | 156784000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and Agios Pharmaceuticals, Inc. from 2014 to 2023. Perrigo, a global leader in over-the-counter health products, consistently outspent Agios, a biotech firm focused on cancer therapies, by a significant margin. In 2023, Perrigo's SG&A expenses were approximately 10 times higher than Agios's, highlighting its expansive operational scale. Over the decade, Agios's SG&A expenses grew by over 500%, reflecting its aggressive growth strategy. Meanwhile, Perrigo's expenses showed a steadier increase of around 90%, indicating a more mature market position. These trends underscore the contrasting business models and market strategies of these two companies, offering valuable insights into their financial health and strategic priorities.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Agios Pharmaceuticals, Inc. vs Novavax, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.